{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T05:49:03Z","timestamp":1649051343210},"reference-count":36,"publisher":"Bentham Science Publishers Ltd.","issue":"46","license":[{"start":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T00:00:00Z","timestamp":1556236800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2019,4,26]]},"abstract":"<jats:sec>\n<jats:title \/>\n<jats:p \/>\n<\/jats:sec>","DOI":"10.2174\/138161282446190426120024","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T10:14:08Z","timestamp":1556532848000},"page":"5489-5490","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mineralocorticoid Receptor Antagonists in Cardiovascular Medicine: Looking for the Forest Among the Trees"],"prefix":"10.2174","volume":"24","author":[{"given":"Konstantinos V.","family":"Stavropoulos","sequence":"first","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine Hippokration Hospital of Thessaloniki Aristotle University of Thessaloniki Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos P.","family":"Imprialos","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine Hippokration Hospital of Thessaloniki Aristotle University of Thessaloniki Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Doumas","sequence":"additional","affiliation":[{"name":"Veterans Affairs Medical Center George Washington University Washington, DC, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles J.","family":"Faselis","sequence":"additional","affiliation":[{"name":"Veterans Affairs Medical Center George Washington University Washington, DC, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0140-6736(62)92199-2","volume":"1","author":"Cranston W.I.","year":"1962","unstructured":"Cranston WI, Juel-Jensen BE. Lancet, The effects of spironolactone and chlorthalidone on arterial pressure., 1962, 1, 1161-1164,","journal-title":"Lancet"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.2174\/1381612823666170206154706","volume":"23","author":"Faselis C.","year":"2017","unstructured":"Faselis C, Boutari C, Doumas M. Curr Pharm Des, Novel drugs for hypertension and heart failure: struggling for a place under the sun., 2017, 23, 1540-1550,","journal-title":"Curr Pharm Des"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1517\/14656566.2015.1083977","volume":"16","author":"Sarafidis P.A.","year":"2015","unstructured":"Sarafidis PA, Georgianos PI, Bakris GL. Expert Opin Pharmacother, Advances in treatment of hyperkalemia in chronic kidney disease., 2015, 16, 2205-2215,","journal-title":"Expert Opin Pharmacother"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","volume":"32","author":"Pitt B.","year":"2011","unstructured":"Pitt B, Anker SD, Bushinsky DA. Eur Heart J, Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial., 2011, 32, 820-828,","journal-title":"Eur Heart J"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","volume":"372","author":"Weir M.R.","year":"2015","unstructured":"Weir MR, Bakris GL, Bushinsky DA. N Engl J Med, Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors., 2015, 372, 211-221,","journal-title":"N Engl J Med"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","volume":"372","author":"Packham D.K.","year":"2015","unstructured":"Packham DK, Rasmussen HS, Lavin PT. N Engl J Med, Sodium zirconium cyclosilicate in hyperkalemia., 2015, 372, 222-231,","journal-title":"N Engl J Med"},{"key":"ref=7","first-page":"e13","volume":"71","author":"Whelton P.K.","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS. Hypertension, 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines., 2018, 71, e13-e115,","journal-title":"Hypertension"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"Williams B.","year":"2018","unstructured":"Williams B, Mancia G, Spiering W. J Hypertens, 2018 ESC\/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension., 2018, 36, 1953-2041,","journal-title":"J Hypertens"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"Williams B.","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S. Lancet, Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial., 2015, 386, 2059-2068,","journal-title":"Lancet"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"Funder J.W.","year":"2016","unstructured":"Funder JW, Carey RM, Mantero F. J Clin Endocrinol Metab, The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline., 2016, 101, 1889-1916,","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"Pitt B.","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ. N Engl J Med, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators., 1999, 341, 709-717,","journal-title":"N Engl J Med"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"Zannad F.","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H. N Engl J Med, Eplerenone in patients with systolic heart failure and mild symptoms., 2011, 364, 11-21,","journal-title":"N Engl J Med"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"Pitt B.","year":"2003","unstructured":"Pitt B, Remme W, Zannad F. N Engl J Med, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction., 2003, 348, 1309-1321,","journal-title":"N Engl J Med"},{"key":"ref=14","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2018.09.011 [Epub ahead of print].","author":"Bayoumi E.","year":"2018","unstructured":"Bayoumi E, Lam PH, Dooley DJ. Am J Med, Spironolactone and outcomes in older patients with heart failure and reduced ejection fraction., 2018, 348, 1309-,","journal-title":"Am J Med"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/01.CIR.0000138680.89536.A9","volume":"110","author":"Mottram P.M.","year":"2004","unstructured":"Mottram PM, Haluska B, Leano R. Circulation, Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure., 2004, 110, 558-565,","journal-title":"Circulation"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski P.","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD. Eur J Heart Fail, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC., 2016, 18, 891-975,","journal-title":"Eur J Heart Fail"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.5414\/CNP72449","volume":"72","author":"Bomback A.S.","year":"2009","unstructured":"Bomback AS, Muskala P, Bald E. Clin Nephrol, Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduced blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage., 2009, 72, 449-456,","journal-title":"Clin Nephrol"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","volume":"20","author":"Mehdi UF","year":"2009","unstructured":"Mehdi UF. J Am Soc Nephrol, ms-Huet B, Raskin P, et al Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy., 2009, 20, 2641-2650,","journal-title":"J Am Soc Nephrol"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","volume":"350","author":"Kolkhof P.","year":"2012","unstructured":"Kolkhof P, Borden SA. Mol Cell Endocrinol, Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics., 2012, 350, 310-317,","journal-title":"Mol Cell Endocrinol"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MNH.0000000000000147","volume":"24","author":"Kolkhof P.","year":"2015","unstructured":"Kolkhof P, Nowack C, Eitner F. Curr Opin Nephrol Hypertens, Nonsteroidal antagonists of the mineralocorticoid receptor., 2015, 24, 417-424,","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.nephro.2017.02.003","volume":"13","author":"Ruilope L.M.","year":"2017","unstructured":"Ruilope LM, Tamargo J. Nephrol Ther, Renin-angiotensin system blockade: Finerenone., 2017, 13, S47-S53,","journal-title":"Nephrol Ther"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/eurheartj\/ehv550","volume":"37","author":"Mulder P","year":"2016","unstructured":"Mulder P. Eur Heart J,  BarreraChimal J, El Moghrabi S, et al Finerenone improves diastolic function in a preclinical model of type 2 diabetes mellitus., 2016, 37, 829-,","journal-title":"Eur Heart J"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/fcp.12170","volume":"30","author":"Lentini S.","year":"2016","unstructured":"Lentini S, Heinig R, Kimmeskamp-Kirschbaum N. Fundam Clin Pharmacol, Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone-results from first-in-man and relative bioavailability studies., 2016, 30, 172-184,","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/cpdd.263","volume":"5","author":"Heining R.","year":"2016","unstructured":"Heining R, Kimmeskamp-Kirschbaum N, Halabi A. Clin Pharmacol Drug Dev, Pharmacokinetics of the novel Non-steroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) in individuals with renal impairment., 2016, 5, 488-501,","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"Pitt B.","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P. Eur Heart J, Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial., 2013, 34, 2453-2456,","journal-title":"Eur Heart J"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","volume":"37","author":"Filippatos G.","year":"2016","unstructured":"Filippatos G, Anker SD, B\u00f6hm M. Eur Heart J, A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease., 2016, 37, 2105-2114,","journal-title":"Eur Heart J"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"Bakris G.L.","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC. JAMA, Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial., 2015, 314, 884-889,","journal-title":"JAMA"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.2174\/1381612825666190215100502","volume":"24","author":"Pantelidis P.","year":"2018","unstructured":"Pantelidis P, Sideris M, Avranas K. Curr Pharm Des, The mechanism of actions of aldosterone and its antagonists in cardiovascular disease., 2018, 24, 5491-5499,","journal-title":"Curr Pharm Des"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.2174\/1381612825666190306163310","volume":"24","author":"Imprialos K.P.","year":"2018","unstructured":"Imprialos KP, Bouloukou S, Kerpiniotis G. Curr Pharm Des, Mineralocorticoid receptor antagonists in essential and resistant hypertension., 2018, 24, 5500-5507,","journal-title":"Curr Pharm Des"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.2174\/1381612825666190311130138","volume":"24","author":"Stavropoulos K.","year":"2018","unstructured":"Stavropoulos K, Papadopoulos C, Koutsampasopoulos K. Curr Pharm Des, Mineralocorticoid receptor antagonists in primary aldosteronism., 2018, 24, 5508-5516,","journal-title":"Curr Pharm Des"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.2174\/1381612825666190219141326","volume":"24","author":"Papademetriou V.","year":"2018","unstructured":"Papademetriou V, Toumpourleka M, Imprialos KP. Curr Pharm Des, Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction., 2018, 24, 5517-5524,","journal-title":"Curr Pharm Des"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.2174\/1381612825666190219140342","volume":"24","author":"Papagiannis A.","year":"2018","unstructured":"Papagiannis A, Alkagiet S, Tziomalos K. Curr Pharm Des, The role of mineralocorticoid receptor antagonists in the managemnet of heart failure with perserved ejection fraction., 2018, 24, 5525-5527,","journal-title":"Curr Pharm Des"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.2174\/1381612825666190306162658","volume":"24","author":"Sarafidis P.A.","year":"2018","unstructured":"Sarafidis PA, Memmos E, Alexandrou M-E, Papagianni A. Curr Pharm Des, Mineralocorticoid receptor antagonists for nephroprotection: Current evidence and future perspectives., 2018, 24, 5528-5536,","journal-title":"Curr Pharm Des"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.2174\/1381612825666190222144359","volume":"24","author":"Kallistratos M.S.","year":"2018","unstructured":"Kallistratos MS, Pittaras A, Theodoulidis I. Curr Pharm Des, Adverse effects of mineralocorticoid receptor antagonist administration., 2018, 24, 5537-5541,","journal-title":"Curr Pharm Des"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.2174\/1381612825666190306162339","volume":"24","author":"Athyros V.G.","year":"2018","unstructured":"Athyros VG, Sachinidis AG, Zografou I. Curr Pharm Des, Boosting the limited use of mineralocorticoid receptor antagonists through new agents for hyperkalemia., 2018, 24, 5542-5547,","journal-title":"Curr Pharm Des"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.2174\/1381612825666190222145116","volume":"24","author":"Dimitriadis K.","year":"2018","unstructured":"Dimitriadis K, Tsioufis C, Iliakis P. Curr Pharm Des, Future anti-aldosterone agents., 2018, 24, 5548-5554,","journal-title":"Curr Pharm Des"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/171859","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T21:41:16Z","timestamp":1558820476000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/171859\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,26]]},"references-count":36,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2019,4,26]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/138161282446190426120024","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4,26]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}